Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Product Name: BPC-157 / TB500 Blend 10mg
(2) Peterson Health Technology, 2025
The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword
Taki format wspiera standaryzacj procedur eksperymentalnych, uatwia przygotowanie materiau do analiz porwnawczych oraz moe mie znaczenie w projektach obejmujcych ocen stabilnoci i powtarzalnoci przygotowania odczynnika
US$ 26.73
US$ 20.05
US$ 25.80
US$ 21.91
US$ 22.75
